Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc.（CGEM）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · CGEM · 截至 2025年9月30日
股东结构概览
146
机构持有人数
$362.47M
机构持仓总市值
▼ $108.96M vs Q2
61.46M
总流通股
freeFloat 72.04%
61.08M
13F 申报持股数
▼ 1.53M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
CGEM 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BIOIMPACT CAPITAL LLC biological products, (no diagnostic substances) | 7.65M | 12.96% | 12.96% | $45.35B | Nov 14, 2025 | — held |
LYNX1 CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 5.77M | 9.77% | 9.77% | $34.19B | Nov 13, 2025 | ▲ 1.37M |
BVF INC/IL biological products, (no diagnostic substances) | 5.75M | 9.74% | 9.74% | $34.10B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 4.17M | 7.07% | 7.07% | $24.73B | Nov 12, 2025 | ▼ 48.0K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.94M | 4.99% | 4.99% | $17.45B | Nov 7, 2025 | ▼ 76.8K |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) biological products, (no diagnostic substances) | 2.93M | 4.96% | 4.96% | $17.36B | Nov 14, 2025 | ▼ 928.5K |
BLUE OWL CAPITAL HOLDINGS LP biological products, (no diagnostic substances) | 2.51M | 4.25% | 4.25% | $14.89B | Nov 12, 2025 | ▲ 125.0K |
KYNAM CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 2.30M | 3.90% | 3.90% | $13.65B | Nov 14, 2025 | ▲ 206.2K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 1.98M | 3.36% | 3.36% | $11.77B | Nov 14, 2025 | ▼ 629.3K |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 1.92M | 3.26% | 3.26% | $11.41B | Nov 14, 2025 | — held |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
22
增持
+3.60M 股3
新建仓
首次建仓15
减持
−3.26M 股0
清仓
完全退出净股数变化（前50家）
+343.0K
+3.60M / −3.26M
净新增持仓人
+10
新建 3 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
CGEM 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
1
买入笔数
3
卖出笔数
0.33
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Michaelson Jennifer Chief Scientific Officer | May 5, 2026 | Sale | 7,800 | $14.60 | $113.9K | 167.0K | Form 4 ↗ |
Michaelson Jennifer Chief Scientific Officer | May 5, 2026 | Sale | 200 | $15.58 | $3.1K | 166.8K | Form 4 ↗ |
Michaelson Jennifer Chief Scientific Officer | Mar 5, 2026 | Sale | 8,000 | $15.68 | $125.4K | 170.8K | Form 4 ↗ |
Michaelson Jennifer Chief Scientific Officer | Feb 25, 2026 | Sale | 1,780 | $14.14 | $25.2K | 174.8K | Form 4 ↗ |
Michaelson Jennifer Chief Scientific Officer | Feb 23, 2026 | Sale | 1,752 | $13.99 | $24.5K | 180.2K | Form 4 ↗ |
Michaelson Jennifer Chief Scientific Officer | Feb 24, 2026 | Sale | 3,601 | $14.47 | $52.1K | 176.6K | Form 4 ↗ |
AHMED NADIM President and CEO | Feb 24, 2026 | Sale | 13,515 | $14.47 | $195.6K | 390.8K | Form 4 ↗ |
Jones Jeffrey Alan Chief Medical Officer | Feb 24, 2026 | Sale | 4,582 | $14.47 | $66.3K | 160.0K | Form 4 ↗ |
SUMER JACQUELYN L Chief Legal Officer | Feb 24, 2026 | Sale | 3,601 | $14.47 | $52.1K | 128.1K | Form 4 ↗ |
Jones Jeffrey Alan Chief Medical Officer | Feb 20, 2026 | Sale | 4,982 | $13.62 | $67.9K | 164.6K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Cullinan Therapeutics, Inc.（CGEM）主要由机构投资者持有，机构持股比例约为 99.4%。公司内部人员持股约 27.96%，散户及公众持股约占剩余的 0.00%。
Cullinan Therapeutics, Inc. 最大机构股东为 BIOIMPACT CAPITAL LLC，截至 September 30, 2025 持有约 7.65 million 股，占总流通股的 12.96%。
目前共有 146 家机构持有 CGEM 股票，合计持仓市值约 $362,471,981，数据来源为最新 SEC 13F 申报。
常见问题
CGEM ownershipCullinan Therapeutics, Inc.（CGEM）主要由机构投资者持有，机构持股约 99.4%。最大股东为 BIOIMPACT CAPITAL LLC，持股比例 12.96%。内部人员持股约 27.96%。数据来源 SEC Form 13F，截至 September 30, 2025。